<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">94823</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Primary hyperaldosteronism: diagnosis and treatment. A new look at the problem. According to the materials of the Russian Association of Endocrinologists clinical guidelines for primary hyperaldosteronism diagnosis and treatment</article-title><trans-title-group xml:lang="ru"><trans-title>Первичный гиперальдостеронизм: диагностика и лечение. Новый взгляд на проблему. По материалам Проекта клинических рекомендаций Российской ассоциации эндокринологов по диагностике и лечению первичного гиперальдостеронизма</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Melnichenko</surname><given-names>G. A</given-names></name><name xml:lang="ru"><surname>Мельниченко</surname><given-names>Г. А</given-names></name></name-alternatives><bio xml:lang="ru"><p>акад. РАН, д-р мед. наук, проф., дир. ФГБУ ЭНЦ</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Platonova</surname><given-names>N. M</given-names></name><name xml:lang="ru"><surname>Платонова</surname><given-names>Н. М</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, гл. науч. сотр. отд-ния терапии с группой патологии метаболизма и ожирения ФГБУ ЭНЦ</p></bio><email>doc-platonova@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Beltsevich</surname><given-names>D. G</given-names></name><name xml:lang="ru"><surname>Бельцевич</surname><given-names>Д. Г</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, гл. науч. сотр. отд. хирургии ФГБУ ЭНЦ</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Yukina</surname><given-names>M. Yu</given-names></name><name xml:lang="ru"><surname>Юкина</surname><given-names>М. Ю</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, ст. науч. сотр. отд. терапевтической эндокринологии, ФГБУ ЭНЦ</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Molashenko</surname><given-names>N. V</given-names></name><name xml:lang="ru"><surname>Молашенко</surname><given-names>Н. В</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, вед. науч. сотр. отд. терапевтической эндокринологии ФГБУ ЭНЦ</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Troshina</surname><given-names>E. A</given-names></name><name xml:lang="ru"><surname>Трошина</surname><given-names>Е. А</given-names></name></name-alternatives><bio xml:lang="ru"><p>чл.-кор. РАН, д-р мед. наук, проф., зав. отд-нием терапии с группой патологии метаболизма и ожирения ФГБУ ЭНЦ</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Endocrinology research center of the Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Эндокринологический научный центр» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2017</year></pub-date><volume>19</volume><issue>4</issue><issue-title xml:lang="en">VOL 19, NO4 (2017)</issue-title><issue-title xml:lang="ru">ТОМ 19, №4 (2017)</issue-title><fpage>75</fpage><lpage>85</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/94823">https://consilium.orscience.ru/2075-1753/article/view/94823</self-uri><abstract xml:lang="en"><p>The article presents the project of the Russian Association of Endocrinologists clinical guidelines for primary hyperaldosteronism (PH) diagnosis and treatment, which provides the modern algorithm for examining patients with PH and also is considered the basic principles of laboratory, instrumental diagnosis and pathogenetic treatment approaches.</p></abstract><trans-abstract xml:lang="ru"><p>В статье представлен Проект клинических рекомендаций Российской ассоциации эндокринологов по диагностике и лечению первичного гиперальдостеронизма (ПГА), в котором представлен современный алгоритм обследования пациентов с ПГА, рассмотрены основные принципы лабораторной, инструментальной диагностики и патогенетические подходы к лечению.</p></trans-abstract><kwd-group xml:lang="en"><kwd>aldosterone</kwd><kwd>renin</kwd><kwd>aldosterone-renin ratio</kwd><kwd>aldosterone-producing adenoma</kwd><kwd>adrenal hyperplasia</kwd><kwd>selective suprarenal venous sampling</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>альдостерон</kwd><kwd>ренин</kwd><kwd>альдостерон-рениновое соотношение</kwd><kwd>альдостеронпродуцирующая аденома</kwd><kwd>гиперплазия надпочечников</kwd><kwd>селективный забор крови из надпочечниковых вен</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Milliez P, Girerd X, Plouin P.F et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-8.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Mancia G, Fagard R, Narkiewicz K et al. ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), 2013.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Funder J.W, Carey R.M, Mantero F et al. The Management of Primary Aldosteronism Case Detection Diagnosis and Treatment An Endocrine Society Clinical Practice Guideline.J Clin Endocrinol Metab 2016; 101 (5): 1889-916.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Funder J.W, Carey R.M, Fardella C et al. An Endocrine Society Clinical Practice Guidelines. Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. J Clin Endocrinol Metab 2008; 93 (9): 3266-81.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Conn J.W. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J lab Clin Med 1955; 45: 3-17.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Conn J.W, Cohen E.L, Rovner D.R, Nesbit R.M. Normokalemic Primary Aldosteronism.A Detectable Cause of Curable “Essential” Hypertension. Jama 1965; 193: 200-6.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Conn J.W. The Evolution of Primary Aldosteronism 1954-1967. Acedemic Press Inc.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kaplan N.M. Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism. Ann Intern Med 1967; 66: 1079-90.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Fishman L.M, Kuchel O, Liddle G.W et al. Incidence of primary aldosteronism uncomplicated “essential” hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria. Jama 1968; 205: 497-502.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sample. Br Med J 1976; 2: 554-6.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Tucker R.M, Labarthe D.R. Frequency of surgical treatment for hypertension in adults at the Mayo Clinic from 1973 through 1975. Mayo Clin Proc 1977; 52: 549-5.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Streeten D.H, Tomycz N, Anderson G.H. Reliability of screening methods for the diagnosis of primary aldosteronism. Am J Med 1979; 67: 403-13.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Sinclair A.M, Isles C.G, Brown I et al. Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987; 147: 1289-93.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Andersen G.S, Toftdahl D.B, Lund J.O et al. The incidence rate of phaeochromocytoma and Conn’s syndrome in Denmark, 1977-1981. J Hum Hypertens 1988; 2: 187-9.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Grim C.E, Weinberger M.H, Higgins J.T, Kramer N.J. Diagnosis of secondary forms of hypertension. A comprehensive protocol. Jama 1977; 237: 1331-5.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Gordon R.D, Stowasser M, Tunny T.J et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-8.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Fardella C.E, Mosso L, Gomez-Sanchez C et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-7.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Lim P.O, Dow E, Brennan G et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14: 311-5.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Loh K.C, Koay E.S, Khaw M.C et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-9.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Mulatero P, Stowasser M, Loh K.C et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clinic Endocrinol Metabo 2004; 89: 1045-50.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Mosso L, Carvajal C, Gonzalez A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-5.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Schwartz G.L, Turner S.T. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005; 51: 386-94.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Hannemann A, Bidlingmaier M, Friedrich N et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. Eur J Endocrinol 2012; 167: 7-15.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Rossi G.P, Bernini G, Caliumi C et al. A prospective study of the prevalence of primary aldosteronism in 1.125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-300.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Milliez P, Girerd X, Plouin P.F et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-8.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Stowasser M, Sharman J, Leano R et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol and Metab 2005; 90: 5070-6.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Rossi G.P, Cesari M, Cuspidi C et al. Long - term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013; 62: 62-9.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Reincke M, Fischer E, Gerum S et al. German Conn’s Registry-Else Kroner-Fresenius-Hyperaldosteronism R. Observational study mortality in treated primary aldosteronism. The German Conn's Registry. Hypertension 2012; 60 (3): 618-24.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Lin Y.H, Lin L.Y, Chen A et al. Adrenalectomy improves increased carotid intima - media thickness and arterial stiffness in patients with aldosterone producing adenoma. Atherosclerosis 2012; 221: 154-9.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Stowasser M, Gordon R.D, Gunasekera T.G et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘nonselective’ screening of hypertensive patients. J Hypertens 2003; 21: 2149-57.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Catena C, Colussi G, Lapenna R et al. Long - term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-8.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Wu V.C, Kuo C.C, Wang S.M et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. J Hypertens 2011; 29: 1778-86.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Трошина Е.А, Бельцевич Д.Г, Молашенко Н.В. Диагностика и дифференциальная диагностика первичного гиперальдостеронизма. Клин. медицина. 2009; 5: 15-20.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Montori V.M, Schwartz G.L, Chapman A.B et al. Validity of the aldosterone - renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001; 76: 877-882.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Stowasser M, Ahmed A.H, Pimenta E et al. Factors affecting the aldosterone/renin ratio. Horm Metab Res 2012; 44: 170-6.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Montori V.M, Schwartz G.L, Chapman A.B et al. Validity of the aldosterone - renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001; 76: 877-82.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Fardella C.E, Mosso L, Gomez-Sanchez C et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-7.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Mosso L, Carvajal C, González A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42 (2): 161-5.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Gallay B.J, Ahmad S, Xu L et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone - renin ratio. Am J Kidney Dis 2001; 37: 699-705.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Tiu S.C, Choi C.H, Shek C.C et al. The use of aldosterone - renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab 2005; 90: 72-8.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Solar M, Malirova E, Ballon M et al. Confirmatory testing in primary aldosteronism: extensive medication switching is not needed in all patients. Eur J Endocrinol 2012; 166: 679-86.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Young W.F. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 2007; 66: 607-18.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Young W.F. Conventional imaging in adrenocortical carcinoma: update and perspectives. Horm canc 2011; 2: 341-7.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Nwariaku F.E, Miller B.S, Auchus R et al. Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg 2006; 141: 497-502.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Sawka A.M, Young W.F, Thompson G.B et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001; 135: 258-61.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Meyer A, Brabant G, Behrend M. Long - term follow - up after adrenalectomy for primary aldosteronism. World J Surg 2005; 29: 155-9.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Weinberger M.H, Grim C.E, Hollifield J.W et al. Primary aldosteronism: diagnosis, localization, and treatment. Ann Intern Med 1979; 90: 386-95.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Baer L, Sommers S.C, Krakoff L.R et al. Pseudoprimary aldosteronism. An entity distinct from true primary aldosteronism. Circ Res 1970; 27: 203-20.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Priestley J.T, Ferris D.O, Re Mine W.H, Woolner L.B. Primary aldosteronism: surgical management and pathologic findings. Mayo Clin Proc 1968; 43: 761-75.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Young W.F, Stanson A.W, Thompson G.B et al. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004; 136: 1227-35.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Doppman J.L, Gill J.R. Hyperaldosteronism: sampling the adrenal veins. Radiology 1996; 198: 309-12.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Vonend O, Ockenfels N, Gao X et al. Adrenal venous sampling: evaluation of the German Conn’s registry. Hypertension 2011; 57: 990-5.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Mengozzi G, Rossato D, Bertello C et al. Rapid cortisol assay during adrenal vein sampling in patients with primary aldosteronism. Clin Chem 2007; 53: 1968-71.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Auchus R.J, Michaelis C, Wians F.H et al. Rapid cortisol assays improve the success rate of adrenal vein sampling for primary aldosteronism. Ann Surg 2009; 249: 318-21.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Reardon M.A, Angle J.F, Abi-Jaoudeh N et al. Intraprocedural cortisol levels in the evaluation of proper catheter placement in adrenal venous sampling. J Vascular Interv Radiol 2011; 22: 1575-80.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Rossi G.P. Diagnosis and treatment of primary aldosteronism. Endocrinol Metab Clin North Am 2011; 40: 313-32.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Betz M.J, Degenhart C, Fischer E et al. Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. Eur J Endocrinol 2011; 165: 301-6.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Viste K, Grytaas M.A, Jorstad M.D et al. Efficacy of adrenal venous sampling is increased by point of care cortisol analysis. Endocr Connect 2013; 2: 236-42.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Riester A, Fischer E, Degenhart C et al. Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism. J Clin Endocrinol Metab 2014; 99: E1035-9.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Lim V, Guo Q, Grant C.S et al. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism. J Clin Endocrinol Metab 2014; 99: 2712-19.</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Rossi G.P, Barisa M, Allolio B et al. The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab 2012; 97: 1606-14.</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Stowaser M et al. Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2001; 2; 156-69.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Rossi G.P, Auchus R.J, Brown M et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension 2014; 63: 151-60.</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Webb R, Mathur A, Chang R et al. What is the best criterion for the interpretation of adrenal vein sample results in patients with primary hyperaldosteronism? Ann Surg Oncol 2012; 19: 1881-6.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Mc Mahon G.T, Dluhy R.G. Glucocorticoid - remediable aldosteronism. Cardiol Rev 2004; 12: 44-8.</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Mulatero P, Tizzani D, Viola A et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension 2011; 58: 797-803.</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Dluhy R.G, Anderson B, Harlin B et al. Glucocorticoid - remediable aldosteronism is associated with severe hypertension in early childhood. J Pediatr 2001; 138: 715-20.</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Lifton R.P, Dluhy R.G, Powers M et al. A chimaeric 11 beta - hydroxylase/aldosterone synthase gene causes glucocorticoid - remediable aldosteronism and human hypertension. Nature 1992; 355: 262-5.</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Jonsson J.R, Klemm S.A, Tunny T.J et al. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 1995; 207: 565-71.</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Fardella C.E, Pinto M, Mosso L et al. Genetic study of patients with dexamethasone - suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene. J Clin Endocrinol Metab 2001; 86: 4805-7.</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>So A, Duffy D.L, Gordon R.D et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens 2005; 23: 1477-84.</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Gordon R.D, Stowasser M, Tunny T.J et al. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin Exp Pharmacol Physiol 1991; 18 (5): 283-6.</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Geller D.S, Zhang J, Wisgerhof M.V et al. A novel form of human mendelian hypertension featuring nonglucocorticoid - remediable aldosteronism. J Clin Endocrinol Metab 2008; 93: 3117-23.</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Choi M, Scholl U.I, Yue P et al. K channel mutations in adrenal aldosterone - producing adenomas and hereditary hypertension. Science 2011; 331: 768-72.</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Scholl U.I, Nelson-Williams C, Yue P et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci USA 2012; 109: 2533-8.</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Blumenfeld J.D, Sealey J.E, Schlussel Y et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121: 877-85.</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Harris D.A, Au-Yong I, Basnyat P.S et al. Review of surgical management of aldosterone secreting tumours of the adrenal cortex. Eur J Surg Oncol 2003; 29: 467-74.</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Rossi E, Regolisti G, Negro A et al. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15: 896-902.</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Young W.F. Jr. Minireview: primary aldosteronism - changing concepts in diagnosis and treatment. Endocrinology 2003; 144: 2208-13.</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Lo C.Y, Tam P.C, Kung A.W et al. Primary aldosteronism. Results of surgical treatment. Ann Surg 1996; 224: 125-30.</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>Proye C.A, Mulliez E.A, Carnaille B.M et al. Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surg 1998; 124: 1128-33.</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Wu V.C, Kuo C.C, Wang S.M et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. J Hypertens 2011; 29: 1778-86.</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation>Fourkiotis V, Vonend O, Diederich S et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol 2013; 168: 75-81.</mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation>Sawka A.M, Young W.F, Thompson G.B et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001; 135: 258-61.</mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation>Ishidoya S, Ito A, Sakai K et al. Laparoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J Urol 2005; 174 (1): 40-3.</mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation>Ghose R.P, Hall P.M, Bravo E.L. The classic presenting signs of primary aldosteronism are hypertension. Br J Clin Pharmacol 1999; 48: 756.</mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation>Mattsson C, Young W.F. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006; 2 (4): 198-208.</mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation>Fischer E, Hanslik G, Pallauf A et al. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy. J Clin Endocrinol Metab 2012; 97: 3965-73.</mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation>Weinberger M.H, Grim C.E, Hollifield J.W et al. Primary aldosteronism: diagnosis, localization, and treatment. Ann Intern Med 1979; 90: 386-95.</mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation>Baer L, Sommers S.C, Krakoff L.R et al. Pseudo - primary aldosteronism. An entity distinct from true primary aldosteronism. Circ Res 1970; 27: 203-20.</mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation>Priestley J.T, Ferris D.O, Re Mine W.H, Woolner L.B. Primary aldosteronism: surgical management and pathologic findings. Mayo Clin Proc 1968; 43: 761-75.</mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation>Parthasarathy H.K, Menard J, White W.B et al. A double - blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011; 29 (5): 980-90.</mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation>Karagiannis A, Tziomalos K, Papageorgiou A et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 2008; 9 (4): 509-15.</mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation>Donald T.M. A double - blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011; 29: 980-90.</mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation>Whitworth J.A; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21 (11): 1983-92.</mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation>Milliez P, Girerd X, Plouin P.F et al. Evidence for an increased rate of cardiovascular events in patients ith primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-48.</mixed-citation></ref></ref-list></back></article>
